WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130135
CAS#: 1308677-14-6
Description: Perfluorinated SAHA is an HDAC inhibitor for use in cancer treatment regimens, with demonstrated greater antiproliferative properties than SAHA . PFSAHA has also been shown to have higher selectivity for PA3774, an HDAC-like enzyme from P. aeruginosa, as well as other HDACs, which may prove beneficial for developing novel chemotherapeutic treatments for cancer.
Hodoodo Cat#: H130135
Name: Perfluorinated SAHA
CAS#: 1308677-14-6
Chemical Formula: C14H8F12N2O3
Exact Mass: 480.03
Molecular Weight: 480.210
Elemental Analysis: C, 35.02; H, 1.68; F, 47.48; N, 5.83; O, 10.00
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Perfluorinated SAHA; PFSAHA
IUPAC/Chemical Name: 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N1-hydroxy-N8-phenyloctanediamide
InChi Key: PVEUUUJZCFCCIZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H8F12N2O3/c15-9(16,7(29)27-6-4-2-1-3-5-6)11(19,20)13(23,24)14(25,26)12(21,22)10(17,18)8(30)28-31/h1-5,31H,(H,27,29)(H,28,30)
SMILES Code: O=C(NO)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(NC1=CC=CC=C1)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 480.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Walton JW, Cross JM, Riedel T, Dyson PJ. Perfluorinated HDAC inhibitors as selective anticancer agents. Org Biomol Chem. 2017 Nov 7;15(43):9186-9190. doi: 10.1039/c7ob02339a. PMID: 29072756.
2. Meyners C, Wolff B, Kleinschek A, Krämer A, Meyer-Almes FJ. Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa. Bioorg Med Chem Lett. 2017 Apr 1;27(7):1508-1512. doi: 10.1016/j.bmcl.2017.02.050. Epub 2017 Feb 21. PMID: 28259626.
3. Henkes LM, Haus P, Jäger F, Ludwig J, Meyer-Almes FJ. Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases. Bioorg Med Chem. 2012 Jan 15;20(2):985-95. doi: 10.1016/j.bmc.2011.11.041. Epub 2011 Nov 30. PMID: 22182579.